NCT03764345View on ClinicalTrials.gov

Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

July 2, 2019

Study Completion Date

July 2, 2019

Conditions
Hepatitis C, ChronicChildren, Only
Interventions
DRUG

Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)

Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks

Trial Locations (1)

32511

Pediatric Hepatology, Gastroenterology and Nutrition Department, National Liver Institute, Menoufia University, Shebin El-Koom

All Listed Sponsors
lead

National Liver Institute, Egypt

OTHER

NCT03764345 - Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years | Biotech Hunter | Biotech Hunter